Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Radical hypofractionated radiotherapy for the treatment of non-small-cell lung cancer using 52·5–55 Gy in 20 fractions: the North Wales Cancer Centre experience

Radical hypofractionated radiotherapy for the treatment of non-small-cell lung cancer using... AbstractBackgroundRadical hypofractionated thoracic radiotherapy is the most commonly used radiotherapy schedule for inoperable non-small-cell lung cancer (NSCLC) in the United Kingdom, despite a lack of level I evidence to support its use.PurposeTo supplement existing published retrospective data with a mature data series and provide further evidence to support the use of this schedule in routine clinical practice.Materials and methodsRetrospective analysis of all inoperable NSCLC cases treated with radical hypofractionated radiotherapy with or without induction chemotherapy in the North Wales Cancer Treatment Centre between 2001 and 2011.ResultsOf the 222 patients, 209 (94%) received 55 Gy in 20 fractions (#) and 13 (6%) received 52·5 Gy in 20#. Induction chemotherapy was administered in 121 (55%) cases. The median survival of 28·6 months (95% confidence interval 24·2–32·5) is comparable with previously published survival outcomes for this patient group.ConclusionThe growing body of evidence for this schedule, confirming survival outcomes comparable with internationally accepted results, is sufficient to support its future use in inoperable NSCLC. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Radiotherapy in Practice Cambridge University Press

Radical hypofractionated radiotherapy for the treatment of non-small-cell lung cancer using 52·5–55 Gy in 20 fractions: the North Wales Cancer Centre experience

Journal of Radiotherapy in Practice , Volume 14 (3): 6 – Mar 25, 2015
Download PDF
6 pages

Loading next page...
 
/lp/cambridge-university-press/radical-hypofractionated-radiotherapy-for-the-treatment-of-non-small-G3Ffy7OnrT

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Cambridge University Press
Copyright
© Cambridge University Press 2015 
ISSN
1467-1131
eISSN
1460-3969
DOI
10.1017/S1460396915000138
Publisher site
See Article on Publisher Site

Abstract

AbstractBackgroundRadical hypofractionated thoracic radiotherapy is the most commonly used radiotherapy schedule for inoperable non-small-cell lung cancer (NSCLC) in the United Kingdom, despite a lack of level I evidence to support its use.PurposeTo supplement existing published retrospective data with a mature data series and provide further evidence to support the use of this schedule in routine clinical practice.Materials and methodsRetrospective analysis of all inoperable NSCLC cases treated with radical hypofractionated radiotherapy with or without induction chemotherapy in the North Wales Cancer Treatment Centre between 2001 and 2011.ResultsOf the 222 patients, 209 (94%) received 55 Gy in 20 fractions (#) and 13 (6%) received 52·5 Gy in 20#. Induction chemotherapy was administered in 121 (55%) cases. The median survival of 28·6 months (95% confidence interval 24·2–32·5) is comparable with previously published survival outcomes for this patient group.ConclusionThe growing body of evidence for this schedule, confirming survival outcomes comparable with internationally accepted results, is sufficient to support its future use in inoperable NSCLC.

Journal

Journal of Radiotherapy in Practice – Cambridge University Press

Published: Mar 25, 2015

Keywords: 52.5-55Gy in 20 fractions; hypofractionated; non-small-cell lung cancer; radical; radiotherapy

References

  • The management of lung cancer: a UK survey of oncologists
  • Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer
  • SOCCAR: A randomised phase II trial comparing sequential versus concurrent chemotherapy and radical hypofractionated radiotherapy in patients with inoperable stage III Non-Small Cell Lung Cancer and good performance status.
  • The hazard of accelerated tumour clonogen repopulation during radiotherapy
  • Geographical variation in radiotherapy services across the UK in 2007 and the effect of deprivation
  • Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients
  • CT-planned accelerated hypofractionated radiotherapy in the radical treatment of non-small cell lung cancer
  • The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung
  • Radical radiotherapy in stage I non-small cell lung cancer (NSCLC)-Singapore National Cancer Centre experience
  • Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome
  • Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small cell lung cancer
  • Radical radiotherapy for inoperable non-small cell lung cancer: what factors predict prognosis?
  • Accelerated hypo-fractionated radiotherapy for non small lung cancer: results from 4 UK centres
  • Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial
  • The IASLC lung cancer staging project; proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours
  • Prognostic factors in surgically resected limited-stage, non-small cell carcinoma of the lung
  • Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter